| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2876531 | The Annals of Thoracic Surgery | 2011 | 8 Pages |
Abstract
The survival rate of a large group of continuous flow LVAD patients in a real-world setting after Food and Drug Administration market approval for bridge to transplantation has improved since the clinical trial. These data show that excellent outcomes have been maintained with dissemination of new LVAD technology from a clinical trial phase to more broad based use in the period after market approval.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ranjit MD, Yoshifumi MD, Nicholas G. MD, Randall MD, MPH, Ulrich MD, Peter MD, David J. PhD, Francis D. MD, PhD,